Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
Clinical & Translational Immunology · 2024-01 · 13 (7)
DOI: 10.1002/cti2.1522 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 18.07.2024. Verfasst von Vahid Yaghoubi Naei und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Engineering University of Technology Sydney Sydney NSW Australia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tour de Cure.
Abstract (Originalsprache)
Objectives
Non‐small‐cell lung carcinoma (NSCLC) is the most prevalent and lethal form of lung cancer. The need for biomarker‐informed stratification of targeted therapies has underpinned the need to uncover the underlying properties of the tumor microenvironment (TME) through high‐plex quantitative assays.
Methods
In this study, we profiled resected NSCLC tissues from 102 patients by targeted spatial proteomics of 78 proteins across tumor, immune activation, immune cell typing, immune‐oncology, drug targets, cell death and PI3K/AKT modules to identify the tumor and stromal signatures associated with overall survival (OS).
Results
Survival analysis revealed that stromal CD56 (HR = 0.384, P = 0.06) and tumoral TIM3 (HR = 0.703, P = 0.05) were associated with better survival in univariate Cox models. In contrast, after adjusting for stage, BCLXL (HR = 2.093, P = 0.02) and cleaved caspase 9 (HR = 1.575, P = 0.1) negatively influenced survival. Delta testing indicated the protective effect of TIM‐3 (HR = 0.614, P = 0.04) on OS. In multivariate analysis, CD56 (HR = 0.172, P = 0.001) was associated with better survival in the stroma, while B7.H3 (HR = 1.72, P = 0.008) was linked to poorer survival in the tumor.
Conclusions
Deciphering the TME using high‐plex spatially resolved methods is giving us new insights into compartmentalised tumor and stromal protein signatures associated with clinical endpoints in NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Engineering University of Technology Sydney Sydney NSW Australia.
- Frazer Institute, Faculty of Medicine The University of Queensland Brisbane QLD Australia.
- Queensland Cyber Infrastructure Foundation (QCIF) Ltd The University of Queensland Brisbane QLD Australia.
- The Princess Alexandra Hospital Brisbane QLD Australia.
ORCID-Profile: Arutha Kulasinghe
Förderung
- Tour de Cure
Zitieren
APA
Yaghoubi Naei, V., Monkman, J., Sadeghirad, H., Mehdi, A., Blick, T., Mullally, W., O'Byrne, K., Warkiani, M. E., & Kulasinghe, A. (2024). Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival. Clinical & Translational Immunology, 13(7). https://doi.org/10.1002/cti2.1522
Vancouver
Yaghoubi Naei V, Monkman J, Sadeghirad H, Mehdi A, Blick T, Mullally W, et al. Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival. Clinical & Translational Immunology. 2024;13(7). doi:10.1002/cti2.1522
BibTeX
@article{YaghoubiNaei2024,
author = {Yaghoubi Naei, Vahid and Monkman, James and Sadeghirad, Habib and Mehdi, Ahmed and Blick, Tony and Mullally, William and O'Byrne, Ken and Warkiani, Majid Ebrahimi and Kulasinghe, Arutha},
title = {Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival},
journal = {Clinical & Translational Immunology},
year = {2024},
volume = {13},
number = {7},
doi = {10.1002/cti2.1522}
}
EUVIMED